Journal
CURRENT PHARMACEUTICAL BIOTECHNOLOGY
Volume 22, Issue 8, Pages 1106-1113Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389201021999200917144704
Keywords
MiR-320b; FOXM1; Pancreatic ductal adenocarcinoma (PDAC); cell proliferation; tumor growth; diagnostic marker
Funding
- High-level innovation and entrepreneurship talent introduction funding program of Xuzhou city 2018 [2018TD011]
Ask authors/readers for more resources
miR-320b suppressed pancreatic cancer cell proliferation by targeting FOXM1, providing a potential new diagnostic marker for pancreatic cancer.
Background: Pancreatic ductal adenocarcinoma (PDAC) is the most common and deadly cancer. Surgical resection is the only possible cure for pancreatic cancer but often has a poor prognosis, and the role of adjuvant therapy is urgently explored. Methods: MicroRNAs (miRNAs) play a very important role in tumorigenesis by regulating the target genes. In this study, we identified miR-320b lower-expressed in human pancreatic cancer tissues but relatively higher-expressed in the adjacent non-tumor tissues. Results: Consistently, the expression of miR-320b in different pancreatic cancer cell lines was significantly lower than the normal pancreatic cells. In order to identify the effects of miR-320b on cell growth, we overexpressed miR-320b in PANC-1 and FG pancreatic cancer cell lines, CCK8 and BrdU incorporation assay results showed that miR-320b inhibited cell proliferation. Discussion: We next predicted miR-320b targeted FOXM1 (Forkhead box protein M1) and identified the negative relationship between miR-320b and FOXM1. We also demonstrated that elevated miR-320b expression inhibited tumor growth in vivo. Conclusion: All of these results showed that miR-320b suppressed pancreatic cancer cell proliferation by targeting FOXM1, which might provide a new diagnostic marker for pancreatic cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available